AMILORIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Amiloride Hydrochloride, and when can generic versions of Amiloride Hydrochloride launch?
Amiloride Hydrochloride is a drug marketed by Chartwell Rx, Par Pharm, Sigmapharm Labs Llc, Barr, Rising, Teva, and Watson Labs. and is included in eight NDAs.
The generic ingredient in AMILORIDE HYDROCHLORIDE is amiloride hydrochloride; hydrochlorothiazide. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amiloride hydrochloride; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amiloride Hydrochloride
A generic version of AMILORIDE HYDROCHLORIDE was approved as amiloride hydrochloride; hydrochlorothiazide by BARR on May 10th, 1988.
Summary for AMILORIDE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 65 |
Patent Applications: | 3,477 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in AMILORIDE HYDROCHLORIDE? | AMILORIDE HYDROCHLORIDE excipients list |
DailyMed Link: | AMILORIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for AMILORIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yale University | Phase 1 |
University of Utah | Early Phase 1 |
Center for Addiction and Mental Health | Early Phase 1 |
Pharmacology for AMILORIDE HYDROCHLORIDE
Drug Class | Potassium-sparing Diuretic |
Physiological Effect | Decreased Renal K+ Excretion Increased Diuresis |